Royalty Pharma and Ferring Pharmaceuticals Seal $500 Million Deal for Revolutionary Intravesical Gene Therapy Adstiladrin®!

Exciting Partnership Unleashed: Royalty Pharma’s $500 Million Boost for Ferring’s Breakthrough Bladder Cancer Therapy!

In a groundbreaking collaboration, Royalty Pharma and Ferring Pharmaceuticals have ignited the healthcare landscape. A whopping $500 million pact has been forged, poised to revolutionize treatment for bladder cancer patients. Under this visionary deal, Royalty Pharma will make an upfront payment of $300 million to Ferring, coupled with a potential $200 million milestone payment. The stars are aligning for Ferring’s innovative intravesical gene therapy, Adstiladrin® (nadofaragene firadenovec-vncg), opening doors to cutting-edge treatments and game-changing possibilities.

This strategic alliance provides Ferring with a monumental infusion of non-dilutive capital. The stage is set for Adstiladrin to soar to new heights, expanding manufacturing capacity, accelerating commercialization, and propelling advanced clinical development. With its FDA-approved prowess, Adstiladrin targets high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients, offering renewed hope where it’s needed most.

Royalty Pharma secures a 5.1% percentage royalty on Adstiladrin’s net sales in the United States, with the potential to surge to 8.0% upon hitting key manufacturing milestones. And there’s an expiration date on this royalty journey – expected to gracefully conclude in the early to mid-2030s.

Jean-Frédéric Paulsen, the visionary Executive Chairman of Ferring Pharmaceuticals, hails this monumental investment as a testament to Adstiladrin’s immense potential. With bladder cancer standing as the sixth most prevalent cancer in the United States, and NMIBC constituting 75% of fresh cases, Adstiladrin’s impact cannot be overstated. This therapy shines as a beacon of innovation, reshaping treatment paradigms for high-risk BCG-unresponsive NMIBC patients.

Bipin Dalmia, the driving force behind Ferring’s Global Head, Uro-Oncology Franchise, echoes this sentiment, projecting Adstiladrin to redefine the gold standard of care. A strategic leap forward in the field, this therapy holds the promise of rewriting the rules for urothelial cancers, energizing research and progress.

Pablo Legorreta, the visionary founder and CEO of Royalty Pharma, celebrates this milestone as a resounding validation of their strategy. Adstiladrin marks the pioneering gene therapy addition to their diverse royalty portfolio, brimming with blockbuster potential. With this partnership, Royalty Pharma fuels the launch of Adstiladrin, empowering Ferring to reach countless patients, scripting a transformative chapter in healthcare.

This is more than a collaboration; it’s a catalyst for change. Royalty Pharma and Ferring Pharmaceuticals are scripting a narrative of hope, progress, and innovation. The stage is set, the investment is poised, and Adstiladrin is primed to make an indelible mark on medical history.

About Adstiladrin

Adstiladrin®, also known as nadofaragene firadenovec-vncg, represents a breakthrough in medical science. This gene therapy holds immense promise as a treatment for adults battling BCG-unresponsive NMIBC, a challenging form of bladder cancer. Imagine a non-replicating adenovirus, acting as a molecular messenger, delivering the precious cargo of interferon alfa-2b gene into the bladder’s very cells. Every three months, through a catheter, this therapy awakens the patient’s own bladder wall cells, turning them into vigilant defenders against cancer.

The story continues within the cellular walls. The vector, like a masterful conductor, orchestrates the release of the interferon gene. The cells themselves become champions, translating the gene’s message into an outpouring of interferon alfa-2b protein. This protein, akin to a guardian angel, mirrors the body’s natural defense mechanism against cancer, but in amplified form. The result? A squadron of interferon microfactories, standing strong against the relentless advance of cancer.

The journey to this point involved a clinical trial program, a testament to human dedication. Picture 157 patients, all with high-grade, BCG-unresponsive NMIBC, who had previously received BCG treatment without success. They became the pioneers, the heroes of this narrative. And when the moment of truth arrived, on December 16, 2022, the US FDA granted its approval based on the findings of a Phase 3 clinical trial. The statistics told an inspiring tale—over half of the patients with carcinoma in situ (CIS ± Ta/T1) achieved complete response by three months. Even more remarkable, the flame of hope burned bright at 12 months, with 46% of those initial responders continuing to stand tall against high-grade recurrence.

In the tapestry of medical progress, Adstiladrin® shines as a symbol of human ingenuity, resilience, and the unwavering quest for solutions that can change lives.


Enter Adstiladrin, a herald of hope in the realm of medical advancements. This groundbreaking gene therapy, harnessed within a non-replicating adenoviral vector, carries a mission to combat high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) like a valiant knight. Its target: the elusive foe known as carcinoma in situ (CIS), whether it stands alone or stands alongside papillary tumors. In a dance of science and ingenuity, Adstiladrin emerges as a beacon of possibility, offering a new dawn for those who brave this challenging battle.


In the world of medical choices, Adstiladrin comes with both guiding lights and cautionary tales. Picture a parchment filled with intricate details, where the journey begins with “CONTRAINDICATIONS” written in bold. A firm stance is taken: those who bear hypersensitivity to interferon alfa or any of the therapy’s components shall tread another path.

But within this tapestry, warnings and precautions weave their threads. Here, a vital message emerges – a potential risk awaits those who delay cystectomy, a crucial procedure for BCG-unresponsive CIS. The stakes are clear, for delay might awaken a dormant beast, transforming non-invasive foes into invasive titans.

Amidst these words, the specter of immunocompromised individuals hovers. A silent note of caution echoes for those whose defenses may be weakened, urging them to avoid Adstiladrin’s embrace. This tale continues with “DOSAGE AND ADMINISTRATION,” a reminder that Adstiladrin’s journey must unfold through the path of intravesical instillation alone.

The tapestry’s texture shifts as “USE IN SPECIFIC POPULATIONS” takes the stage. Here, a whisper of guidance for those of reproductive potential, a gentle reminder of the intricate dance of life and responsibility.

Yet, amidst all this, a symphony of reactions is depicted – “ADVERSE REACTIONS.” The canvas shimmers with colors of experience, as glucose rises, fatigue weaves its spell, and the urgency of urination takes center stage. Each brushstroke captures a facet of the complex human response, reminding us that every action can trigger a myriad of reactions.

In the grand finale, a call to action resounds. The reader is urged not to be a silent observer but a storyteller of their own experiences. The stage is set with a spotlight on reporting, a pathway to shaping the evolving narrative of medical understanding.

Thus, the tale concludes with an invitation – a number to call, a link to visit – a reminder that this tapestry, this story of Adstiladrin, is far from being one-sided. It’s a journey shared, a symphony played in collaboration, where every voice has its role, its significance, its part in the grand narrative of healthcare.

About Royalty Pharma plc

In the heart of the ever-evolving biopharmaceutical landscape, a trailblazer emerged in 1996 under the name Royalty Pharma. Imagine a symphony of innovation where this entity takes center stage as the grand conductor. Like a collector of rare gems, Royalty Pharma became the beholder of biopharmaceutical royalties, igniting a dance of collaboration that spans the spectrum from academic dreams to global giants.

From the hallowed halls of academia and research hospitals to the nimble strides of small biotech companies, all the way to the juggernauts of pharmaceutical prowess, Royalty Pharma weaves a tapestry of partnerships. Each thread binds to therapies that commandeer the spotlight, their top-line sales like the crescendo of a symphonic masterpiece. The story unfolds with a portfolio rich in diversity, embracing the likes of Vertex’s transformative Trikafta trio, the empowering symphony of Biogen’s Tysabri, and the resilience of Johnson & Johnson’s Tremfya.

Yet, the tale doesn’t end with collecting royalties; it’s a saga of nurturing innovation. Royalty Pharma emerges as both patron and partner, wielding influence in the birth of new therapies. With a flourish, it steps onto the stage of late-stage clinical trials, and with a nod to the future, it enters into exchanges for royalties. And oh, the transformation doesn’t stop there—it extends to the very concept of innovation. Royalty Pharma, like a phoenix, breathes new life into existing royalties, a dance of rebirth that keeps the momentum alive.

This saga is painted with hues of achievement and anticipation. The portfolio doesn’t just boast the present; it weaves dreams of tomorrow, with development-stage candidates standing in the wings, waiting for their moment to shine. In this symphony, Royalty Pharma orchestrates not just transactions, but a transformational journey, reminding us that innovation isn’t just about the now, but about nurturing a future where medical breakthroughs become the anthem of human progress.

About Ferring Pharmaceuticals

In the picturesque landscape of biopharmaceutical innovation, a trailblazer emerged under the name Ferring Pharmaceuticals. Imagine a world where the quest for better lives and the joy of new beginnings unite. With the headquarters nestled in Saint-Prex, Switzerland, Ferring stands as a beacon of dedication, a sentinel of research-driven passion.

As you step into this realm, the air is infused with a sense of purpose. Ferring isn’t just a company; it’s a mission. It’s a symphony of commitment echoing across continents. The spotlight here shines on reproductive medicine and women’s health, as well as carving a niche within the intricate domains of gastroenterology and urology. But this story isn’t just about treatments; it’s about weaving dreams. For over half a century, Ferring has been crafting the tapestry of solutions that span the journey from conception to birth, a testament to their unyielding dedication to mothers and babies.

Here, history isn’t just written; it’s a legacy that transcends time. Founded in 1950, Ferring’s story continues to unfold, a tale of growth, of nurturing ideas, and of fostering innovation. Yet, in this vast landscape, it’s the people who breathe life into the narrative. A mosaic of 7,000 individuals, spread across the world, bring their passion to the canvas of healthcare. They are more than employees; they are the heartbeat of a vision that stretches beyond borders.

In this narrative, geography becomes a mere formality. The canvas of impact is painted across more than 50 countries, each a stroke of dedication, each a testament to the universal reach of Ferring’s purpose. As the curtain rises, the global stage takes shape – 100 countries united in embracing Ferring’s offerings, a celebration of human ingenuity and a reminder that care knows no boundaries.

Amidst the grandeur, Ferring Pharmaceuticals emerges as a tale of compassion, a story where the desire to uplift lives merges with the art of science. It’s not just a name; it’s a melody, a symphony that resonates with the essence of human potential, weaving brighter futures, one innovation at a time.


Steering the legal course for Royalty Pharma were the adept minds of Goodwin Procter LLP and Fenwick & West LLP, orchestrating a symphony of legal prowess. Meanwhile, the legal compass for Ferring found its true north with the guidance of Orrick, Herrington & Sutcliffe LLP, weaving a tapestry of legal support.

Royalty Pharma Forward-Looking Statements

Within these words lies a tapestry of insights, a glimpse into the intricate world of information. Yet, let it be known that this mosaic, while rich, is not the full canvas; it merely hints at the depths that lie beyond. These words dance in the realm of time, their origin rooted in the date of this very document – a chronicle of knowledge, unless stated otherwise. But remember, the mere presentation of this document or any subsequent sale of securities shall not conjure an illusion that the wisdom contained herein remains unchanging.

Behold, here dwell “forward-looking statements,” echoes of the future as defined by the United States Private Securities Litigation Reform Act of 1995. In these passages, the company’s vision takes shape, a symphony of opinions, expectations, and dreams. From strategies that pave the way to growth, to the vistas of market expansion, these words paint a vivid picture of aspirations. Seek in them the rhythms of terms like “anticipate,” “believe,” and “expect” – beacons illuminating the path to what lies ahead.

Yet, let us tread with caution, for these words are but reflections of management’s present beliefs and the tapestry of available information. They are not certainties etched in stone; reliance on them must be tempered. The tapestry is woven with threads of uncertainty, a dance of risks and unforeseen circumstances. Their sway can lead these words astray, reminding us that control is not absolute. A reminder, too, that these forward-looking verses are bound by the date of this parchment – unchained from a future obligation to revise or update, save where the law requires.

Amidst these lines, you’ll find fragments harvested from the gardens of third-party sources, and the company’s own research – treasures of insight and data. Yet, while the company vouches for these sources’ reliability, their veracity remains unproclaimed, their accuracy not endorsed. As for the tapestry of market data interwoven here, it’s a mosaic built on assumptions and limitations, a nuanced terrain of uncertainty.

In the end, remember, this parchment is but a whisper of Royalty Pharma’s broader narrative. Seek the full saga in their reports, the documents gracing the halls of the U.S. Securities and Exchange Commission – there, the tale finds its resonance and depth.

Leave a Comment